Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Anne E. Bras, Zgjim Osmani, Valerie de Haas, Mojca Jongen-Lavrencic, Jeroen G. te Marvelde, C. Michel Zwaan, Ester Mejstrikova, Paula Fernandez, Tomasz Szczepanski, Alberto Orfao, Jacques J.M. van Dongen, Vincent H.J. van der Velden*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)
14 Downloads (Pure)

Abstract

Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

Original languageEnglish
Pages (from-to)922-927
Number of pages6
JournalBritish Journal of Haematology
Volume193
Issue number5
Early online date7 Nov 2020
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Funding Information:
We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co‐ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6‐2004‐LIFESCIHEALTH‐5 programme of the European Commission (grant LSHB‐CT‐2006‐018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato‐Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).

Funding Information:
We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co-ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).

Publisher Copyright:
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia'. Together they form a unique fingerprint.

Cite this